To: (i) assess if amoxicillin/clavulanate is a useful option for the management of multidrug-resistant/extensively drug-resistant tuberculosis (MDR/XDR-TB); (ii) assess if meropenem/clavulanate is active against Mycobacterium tuberculosis at concentrations achievable in vivo; and (iii) determine whether there was inhibition of meropenem/clavulanate activity in the presence of amoxicillin.
Introduction
Clinical management of multidrug-resistant/extensively drugresistant tuberculosis (MDR/XDR-TB) remains difficult since it requires the use of more toxic second-line drugs, and for a longer period of time, and the treatment success rates are lower than for fully susceptible strains. This is particularly so for those co-infected with HIV. 1 Few new effective drugs other than fluoroquinolones will be available for widespread use in the near future. One approach, therefore, has been to test families of drugs currently approved for other conditions against Mycobacterium tuberculosis (particularly MDR/XDR-TB strains) in in vitro and in vivo assays.
The WHO has grouped together anti-TB drugs for which there are limited data on efficacy. This includes amoxicillin/clavulanate, which has remained on TB reserve drug lists owing to a small number of studies demonstrating in vitro and potential in vivo effectiveness. 2 The existence of targets for b-lactam antibiotics in mycobacteria has been known for some time, as has the lack of efficacy of such antimicrobial agents due to the presence of highly active class A b-lactamase. 3 Recently, it has been reported that the irreversible inhibition of the b-lactamases by clavulanate allows meropenem to have significant activity against M. tuberculosis. In part this is because meropenem appears to have the greatest stability against these b-lactamases.
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Other b-lactamase inhibitors had less or no effect, and meropenem on its own was not effective at concentrations likely to be achieved in vivo. 4 For patients with MDR/XDR-TB, the use of meropenem plus clavulanate also offers the potential for a new useful drug therapy; in the UK clavulanate is not available for human use except in combination with amoxicillin or ticarcillin. 5 Therefore, to utilize a meropenem approach would require co-administration with amoxicillin/clavulanate. One potential problem is that amoxicillin might compete with meropenem for binding to key drug targets.
Based on the above, our aim was to: (i) assess if amoxicillin/ clavulanate is a useful option for the management of MDR/XDR-TB; (ii) assess if meropenem/clavulanate is a good anti-TB drug combination and if this benefit occurs at concentrations of meropenem in combination with clavulanate likely to be achieved in vivo against both drug-susceptible and MDR/XDR-TB clinical strains; and (iii) determine that there was no inhibition of meropenem/ clavulanate activity in the presence of amoxicillin.
Methods
The laboratory strain M. tuberculosis H37Rv and 27 clinical drugsusceptible and drug-resistant TB isolates received at the UK HPA National Mycobacterium Reference Laboratory were selected and subcultured using the Bactec 960 MGIT w system (Becton Dickinson, Sparks, MD, USA), according to the manufacturer's instructions. Of the included strains, 3 were XDR, 16 MDR, 7 were susceptible to isoniazid and rifampicin, and 2 had other resistance patterns.
Susceptibility to different concentrations of meropenem, meropenem/ clavulanate, amoxicillin/meropenem, amoxicillin/clavulanate and amoxicillin/meropenem/clavulanate was tested using the Bactec 960 MGIT w system (Becton Dickinson), following the manufacturer's instructions for drug susceptibility testing (DST) of other TB drugs.
All strains were tested in duplicate to assess reproducibility.
Drugs
Meropenem was provided by Molekula (Gillingham, Dorset, UK), whereas amoxicillin and clavulanate were bought from Sigma-Aldrich (Poole, Dorset, UK). The final concentrations of meropenem tested were based on the concentrations achieved in lung tissue 5 h after the infusion of a 1 g dose (1.6+0.7 mg/L), and amoxicillin concentrations were based on concentrations achievable after administration of 500 mg of amoxicillin three times a day. The full drug panel for each strain can be found in Table 1 . 6 The stock concentration was controlled by MIC determination for ATCC strains: Escherichia coli 25922 for meropenem and amoxicillin, and Escherichia coli 35218 for amoxicillin/clavulanate. Clavulanate was used at one concentration only, 2.5 mg/L, throughout the study.
Results

Susceptibility to amoxicillin
Twenty-eight strains were included: H37Rv and 27 clinical strains. Amoxicillin/clavulanate was tested against all 28 strains: 4/28 (14.29%) strains were resistant to the highest concentration tested of 7.2/2.5 mg/L amoxicillin/clavulanate (all of them were MDR), 10 strains were susceptible to 3.6/2.5 mg/L amoxicillin/ clavulanate, 6 strains were susceptible to 1.8/2.5 mg/L amoxicillin/ clavulanate and 1 strain was susceptible to 0.9/2.5 mg/L amoxicillin/clavulanate. Seven out of 28 (25%) strains were susceptible only to 7.2/2.5 mg/L amoxicillin/clavulanate, i.e. at the top end of the susceptibility range. Of those, four were MDR. Therefore, 8/16 (50%) of the MDR strains were susceptible only to the highest concentration of amoxicillin (plus clavulanate) or were resistant. Two XDR strains were susceptible to 3.6/2.5 mg/L amoxicillin/clavulanate and the other was susceptible to 7.2/2.5 mg/L amoxicillin/clavulanate.
After the addition of meropenem to amoxicillin/clavulanate, six of seven strains for which the MIC of amoxicillin was 7.2 mg/L became susceptible at a concentration of amoxicillin Table 1 . Drugs and concentrations tested for each strain
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Susceptibility to meropenem
All 28 strains were resistant to meropenem alone at the highest concentration tested of 5 mg/L. When adding clavulanate to meropenem, the MIC of meropenem fell by an average of 1.8 dilutions: 5 strains were susceptible to meropenem at 1.28 mg/L and clavulanate at 2.5 mg/L, 11 were susceptible to meropenem at 2.56 mg/L and clavulanate at 2.5 mg/L, and 12 strains were resistant to meropenem at 2.56 mg/L and clavulanate at 2.5 mg/L. When adding amoxicillin to meropenem/ clavulanate, the MIC of meropenem dropped an average of 3.2 dilutions (Figure 1 ).
Reproducibility
Each of the 28 strains was tested in duplicate for six different drug combinations; two were MICs (of meropenem and meropenem/ clavulanate) and four were MIC analyses of different combinations of meropenem/amoxicillin/clavulanate. The MIC of meropenem for all 28 strains was the same in both determinations, yielding a reproducibility of 100%.
For combinations of meropenem/amoxicillin/clavulanate, the overall reproducibility of the assays was 88.4%, ranging from 78.6% (7.2/0.16/2.5 mg/L amoxicillin/meropenem/clavulanate) to 96.4% (3.6/2.56/2.5 mg/L amoxicillin/meropenem/clavulanate).
Discussion
Amoxicillin/clavulanate has shown activity in vitro and in vivo 3, 7 against TB. However, its true value remains controversial.
As current regimens are highly effective, this drug combination has little part to play in the treatment of fully drugsusceptible strains. 2 Nevertheless, amoxicillin has been shown to be useful in vitro against susceptible clinical strains as well as against H37Rv. 8 We have found that at least in vitro it is active against MDR and XDR clinical strains at doses easily achievable in vivo and we believe that it would be a useful adjunct therapy; it might be an additional tool to consider for the management of MDR/ XDR-TB in selected patients in line with current WHO guidelines. Further clinical studies will clarify its true usefulness.
For patients with MDR/XDR-TB, the use of meropenem plus clavulanate offers the potential for a new useful drug therapy; however, in the UK clavulanate is not available for human use except in combination with amoxicillin or ticarcillin. 9 One potential barrier to its use might have been the presence of antagonism between the two b-lactams due to competition for binding to the same penicillin-binding proteins (PBPs).
However, the opposite was found. The addition of a second b-lactam in the presence of clavulanate generated a drop in the MIC for M. tuberculosis clinical strains, probably due to binding to different PBPs. This drop was more significant for meropenem. The relevance of this observation is that by using more than one drug, in this case meropenem and amoxicillin (with clavulanate) in combination, the risk of resistance emerging or treatment failure in strains susceptible only to the highest drug concentration of amoxicillin/clavulanate might be reduced by the addition of this carbapenem. Only further studies and clinical experience will assess whether this is true.
Meropenem alone is inactive against M. tuberculosis, as expected from the existence of the b-lactamase. 4 The addition of clavulanate reduced the MIC of meropenem, suggesting that it could be an effective combination against M. tuberculosis in vitro. This has been observed previously. In the case of MS2  MS2  MS3  MS4  MS4  MS5  MS6  MS7  MS7  OR1  OR1  OR2  OR2  MDR1  MDR2  MDR2  MDR3  MDR3  MDR4  MDR5  MDR5  MDR6  MDR6  MDR7  MDR7  MDR8  MDR8  MDR9  MDR10  MDR10  MDR11  MDR11  MDR12  MDR12  MDR13  MDR14  MDR14  MDR15  MDR15  MDR16  XDR1  XDR1  XDR2  XDR3 Meropenem/clavulanate alone Addition of 7.2 mg/L amoxicillin Addition of 3.6 mg/L amoxicillin Figure 1 . MIC of meropenem in the presence of a fixed concentration of 2.5 mg/L clavulanate before and after the addition of amoxicillin.
Gonzalo and Drobniewski meropenem/clavulanate, the concentrations of meropenem that showed satisfactory activity were generally higher than those published by Hugonnet et al. 4 This might be due to the different DST technique used here.
Reproducibility improved significantly for the triple combination of amoxicillin/meropenem/clavulanate when adding meropenem at higher concentrations, reaching numbers reported acceptable by the WHO quality assurance scheme for DST. 10 Amoxicillin/clavulanate is active against MDR/XDR-TB in vitro. However, the MICs obtained in this study were frequently near the upper limit of susceptibility. The addition of meropenem to amoxicillin/clavulanate may avoid the emergence of further resistance or failure to these drugs.
b-Lactams have a long history of clinical use with excellent tolerance. The main disadvantages of meropenem for TB use are the dosing, i.e. three times a day intravenously, and the likely long duration of treatment for TB, and its high cost. However, in patients with few or no therapeutic options, such as those with MDR/XDR-TB, these antibiotics would be a valid choice, particularly in middle/high-income settings, provided that they are proven to be active in vivo. This triple therapy would be a useful therapeutic option for MDR/XDR-TB patients and avoid the emergence of further resistance to TB drugs or therapeutic failure.
The DST technique used here is already routinely used in mycobacteriology laboratories and it would be relatively straightforward to implement for meropenem/amoxicillin/clavulanate testing in those laboratories that already use the Bactec 960 MGIT w system.
